Is it Possible to Accurately Determine Content of Botulinum Neurotoxin Type A in Drug Products?

Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used both for cosmetic purposes and to treat a variety of neurological disorders. In somepreparations, theBoNT/A protein form part of a multi-protein complex. Although the accompanying proteins are considered to play no role in the mechanism of action, their presence has raised concerns regarding the amount of total protein administered, sensitization to the preparation, and the formation of neurotoxin neutralizing antibodies leading to therapeutic failure. Preparations that contain only the BoNT/ A protein could potentially limit the development of such an immune response. Hence, it is important to knowhowmuchBoNT/Aprotein is present. The article by Dr Jürgen Frevert published in this issue of Drugs in R&D describes the evaluation of the BoNT/A concentration in three formulations of licensed therapeutic preparations using a sensitive sandwich ELISA assay developed in-house. Only Xeomin /Bocouture contains pure BoNT/A protein and is claimed to have the highest purity and specific activity of the formulations tested. The study is relevant for the characterization of therapeutic preparations of botulinum toxin but is potentially controversial. It is therefore essential that the information presented is correct and is adequately scrutinized. The conclusions of the paper appear to be based on rather limited and variable data, particularly for products other than Xeomin , and should ideally be supported by more focused experimental studies. The claim that the new immunoassay is able to detect only neurotoxin is potentially speculative. It is claimed that antibodies have no ability to detect additional complexing proteins/other clostridial proteins that are known to be present in products other than Xeomin but no direct evidence of this specificity is directly presented in this paper. The main argument is that not all toxin A products are of the same purity and that a particular brand may be of lowest specific activity, despite the authors own claim of no difference in clinical use and in laboratory mouse bioassays studies. This assertion is not entirely novel as a previous paper by Ekong et al. reached the same conclusion for the licensed therapeutic toxin A products at that time. The conclusion then was based on the observation of differences in the ratio of immunodetected toxin to their biological activity. The capture antibody ELISA methodology described in the 1995 paper is virtually identical to the method published here. Although particular product brands were not specifically identified in the previous publication, those familiar with these products would have been able to calculate that for Dysport , the toxin A content was approximately 2.0 ng/500 dose that is lethal to 50% of animals tested (LD50) [0.4 ng/100 LD50], which is lower than the content claimed for this brand and slightly lower than, although comparable to, the value reported by Dr Frevert. It is highly likely that further values will be calculated in other laboratories as the results are both method and reagent specific. It may not be possible to be certain that a COMMENTARY Drugs R D 2010; 10 (2): 91-92 1179-6901/10/0002-0091